Oura Health

Oura Health Ltd. (commonly known as Oura) is a Finnish health technology company founded in 2013, with its headquarters in Oulu, Finland, and additional operations in Helsinki, Finland, and San Francisco, USA. The company's parent entity is in the process of relocating to Delaware, USA. Oura is a privately held, venture capital-backed company with approximately 900 employees as of late 2025/early 2026. It reported revenue of $1 billion in 2025 and achieved a valuation of $11 billion during its Series E funding round in the same year.

Oura's primary product is the Oura Ring, a wellness wearable smart ring designed to track and promote sleep quality, performance, and overall health. The ring's advanced sensors continuously monitor various biometric data, including sleep stages, heart rate, heart rate variability, body temperature, respiratory rate, and physical activity. This data is processed through a companion smartphone app that provides personalized daily scores for sleep, readiness, and activity, along with actionable insights. The company also offers subscription-based analytics and guidance, and has expanded its features to include 24/7 heart rate monitoring, blood oxygen monitoring, period prediction, and women's health insights. Oura is also venturing into chronic condition management, offering features such as "cardiovascular age" assessment.

Oura Health is an active litigant in patent disputes, operating as both a defendant and a plaintiff in two-way litigation. The company is currently a defendant in one tracked case, Omni Medsci, Inc. v. Fossil et al., filed in the Eastern District of Texas in 2024. Oura has also actively asserted its patent portfolio, notably securing a favorable ruling from the U.S. International Trade Commission (ITC) against Ultrahuman, which resulted in an import and sales ban on Ultrahuman smart rings in the U.S., and a settlement with RingConn in 2025. The company has initiated patent infringement suits against other competitors, including Circular SAS in the Western District of Texas, and filed lawsuits against Samsung and Zepp Health in 2025. Conversely, Oura was previously a defendant in a patent infringement case brought by ConnectQuest, LLC in the Western District of Texas, which was dismissed in April 2024, likely following a confidential settlement. These cases indicate a strategic focus on defending and enforcing its intellectual property in the competitive wearable technology market, often in prominent patent litigation venues.